
Sign up to save your podcasts
Or


Good RCT this week, investigating the CD20 B cell inhibitor obinutuzumab for SLE. Sign up for my newsletter if you would like to have a read-along companion piece!
Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2516150
Landing Page: https://ebrheum.com/
Substack: https://autoimmunedevreport.substack.com/
By Michael Putman4.9
114114 ratings
Good RCT this week, investigating the CD20 B cell inhibitor obinutuzumab for SLE. Sign up for my newsletter if you would like to have a read-along companion piece!
Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2516150
Landing Page: https://ebrheum.com/
Substack: https://autoimmunedevreport.substack.com/

504 Listeners

298 Listeners

128 Listeners

3,374 Listeners

1,150 Listeners

120 Listeners

194 Listeners

518 Listeners

68 Listeners

5 Listeners

375 Listeners

183 Listeners

188 Listeners

19 Listeners

6 Listeners